1. Scrip
  2. >>Business
  3. >>Earnings

CEO Sets Strides For Growth With Endo Execs

Stelis Signals Listing, Focus Shift

 
• By Vibha Ravi

Appointing executives from Endo in key positions, Strides' CEO has set up a team to deliver growth, though the impact of ranitidine withdrawal and COVID-19 will defer a revenue target of $800m. Meanwhile, Stelis Biopharma signals a shift in focus from biologics development to CDMO opportunities and is poised for a stock exchange listing. 

A businessman appoints a leader to the head of the team. Creation of an effective teams of specialists for the implementation of a new project. HR recruiting. Management appointment. nepotism
Strides' CEO Has Set Up A High-Powered Team To Drive Growth • Source: Shutterstock

Like a soccer team manager, CEO and managing director R Ananthanarayanan is carefully choosing the players on his squad at Strides Pharma Science Limited. Having spent nearly 13 months getting a feel of the company and the competitive field, he has now picked two senior executives from Endo International plc to help implement a strategy that involves a focus on US and other regulated markets for future growth.

Endo’s former executive vice president and chief operating officer Terrance Coughlin is set to join Strides Pharma as CEO-US, while its executive vice-president for international pharmaceuticals, Rahul Garella, will be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.